Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.66 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395810 | 1.00 | OPRD1 (0.66) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL16570950 | 1.00 | OPRD1 (0.66) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL28468334 | 0.89 | OPRM1 (0.62) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL29416620 | 0.85 | OPRD1 (0.78) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL547917 | 0.85 | OPRD1 (0.78) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL28470432 | 0.84 | OPRD1 (0.63) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL10243104 | 0.84 | OPRM1 (0.65) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL3475523 | 0.83 | OPRD1 (0.88) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Morphine SCHEMBL28712434 | 0.83 | OPRD1 (0.78) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Codeine SCHEMBL4730550 | 0.82 | OPRD1 (0.72) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2025-04-10 | — | — | US | disclosed |
| CN-116940358-A | Sustained release drug delivery system and related methods | 度勒科特公司 | 2023-10-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ADRA2A, ADRA2C, OPRM1 | OPRD1 11/4885OPRM1 3/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.